<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS108044</article-id>
<article-id pub-id-type="doi">10.1101/2020.12.08.416297</article-id>
<article-id pub-id-type="archive">PPR251079</article-id>
<article-version article-version-type="publisher-id">3</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gabitzsch</surname>
<given-names>Elizabeth</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Safrit</surname>
<given-names>Jeffrey T.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Verma</surname>
<given-names>Mohit</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rice</surname>
<given-names>Adrian</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sieling</surname>
<given-names>Peter</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zakin</surname>
<given-names>Lise</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shin</surname>
<given-names>Annie</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morimoto</surname>
<given-names>Brett</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adisetiyo</surname>
<given-names>Helty</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wong</surname>
<given-names>Raymond</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bezawada</surname>
<given-names>Ashish</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dinkins</surname>
<given-names>Kyle</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balint</surname>
<given-names>Joseph</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peykov</surname>
<given-names>Victor</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garban</surname>
<given-names>Hermes</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Philip</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bone</surname>
<given-names>Pete</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bacon</surname>
<given-names>Andrew</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Drew</surname>
<given-names>Jeff</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sanford</surname>
<given-names>Daniel C.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Spilman</surname>
<given-names>Patricia</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sender</surname>
<given-names>Lennie</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rabizadeh</surname>
<given-names>Shahrooz</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niazi</surname>
<given-names>Kayvan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soon-Shiong</surname>
<given-names>Patrick</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>ImmunityBio, LLC, 9920 Jefferson Blvd., Culver City, CA 90232, USA</aff>
<aff id="A2">
<label>2</label>NantKwest, Inc., 9920 Jefferson Blvd., Culver City, CA 90232, USA</aff>
<aff id="A3">
<label>3</label>IosBio, Unit 6, Sovereign Business Park, Albert Drive, Burgess Hill, West Sussex, RH159TY, United Kingdom</aff>
<aff id="A4">
<label>4</label>Battelle Biomedical Research Center, Columbus, Ohio, USA</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding author: <email>Patrick@Nantworks.com</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>09</day>
<month>12</month>
<year>2020</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref>
<license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">We have developed a dual-antigen COVID-19 vaccine incorporating genes for a modified SARS-CoV-2 spike (S-Fusion) protein and the viral nucleocapsid (N) protein with an Enhanced T-cell Stimulation Domain (N-ETSD) with the potential to increase MHC class I/II responses. The adenovirus serotype 5 platform used, hAd5 [E1-, E2b-, E3-], previously demonstrated to be effective in the presence of Ad immunity, can be delivered in an oral formulation that overcomes cold-chain limitations. The hAd5 S-Fusion + N-ETSD vaccine was evaluated in rhesus macaques showing that a subcutaneous prime followed by oral boosts elicited both humoral and Th1 dominant T-cell responses to both S and N that protected the upper and lower respiratory tracts from high titer (1 x 10<sup>6</sup> TCID<sub>50</sub>) SARS-CoV-2 challenge. Notably, viral replication was inhibited within 24 hours of challenge in both lung and nasal passages, becoming undetectable within 7 days post-challenge.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">To address the ongoing COVID-19 pandemic (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>), particularly in the face of viral evolution and evidence of viral variant resistance to antibodies and convalescent plasma (<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R6">6</xref>), we have developed a vaccine anticipated to protect individuals from SARS-CoV-2 that has the potential to not only elicit robust humoral responses but also activate T cells. The dual-antigen hAd5 S-Fusion + N-ETSD vaccine (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>) expresses a viral spike (S) protein (S-Fusion) fused to a signal sequence that, as predicted based on reports for similar sequences (<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>), in our <italic>in vitro</italic> studies enhances cell-surface expression of the spike receptor binding domain (S RBD) as compared to S wildtype (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2</xref>), the antigen used in the majority of other vaccines being developed. Our vaccine also expresses the viral nucleocapsid (N) protein with an Enhanced T-cell Stimulation Domain (N-ETSD) that directs N to the endo/lysosomal subcellular compartment as demonstrated in Sieling <italic>et al.</italic> (in preprint) (<xref ref-type="bibr" rid="R9">9</xref>) which is predicted to enhance MHC class II responses (<xref ref-type="bibr" rid="R10">10</xref>–<xref ref-type="bibr" rid="R12">12</xref>).</p>
<p id="P3">The SARS-CoV-2 vaccine antigens are delivered by an recombinant human adenovirus serotype 5 (hAd5) [E1-, E2b-, E3-] vector platform (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1A</xref>) we previously developed to rapidly generate vaccines against multiple agents, allowing production of high numbers of doses in a minimal time frame. The hAd5 platform has unique deletions in the early 1 (E1), early 2 (E2b) and early 3 (E3) regions (hAd5 [E1-, E2b-, E3-]), which distinguishes it from other adenoviral vaccine platform technologies under development (<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref>), and allows it to be effective in the presence of pre-existing adenovirus immunity (<xref ref-type="bibr" rid="R16">16</xref>–<xref ref-type="bibr" rid="R19">19</xref>). We have utilized this platform to produce vaccines against viral antigens such as Influenza, HIV-1 and Lassa fever and have shown induction of both antibodies and cell mediated immunity (<xref ref-type="bibr" rid="R18">18</xref>, <xref ref-type="bibr" rid="R20">20</xref>–<xref ref-type="bibr" rid="R23">23</xref>). In 2009, we showed that vaccination of mice with the hAd5 [E1-, E2b-, E3-] vector expressing H1N1 hemagglutinin and neuraminidase genes (<xref ref-type="bibr" rid="R20">20</xref>) elicited both cell-mediated immunity and humoral responses that protected the animals from lethal virus challenge.</p>
<p id="P4">The overwhelming majority of other SARS-CoV-2 vaccines in development target only the wildtype S antigen and are expected to elicit SARS-CoV-2 neutralizing antibody responses. In the development of our vaccine, we prioritized the activation T cells to enhance the breath and duration of protective immune responses (<xref ref-type="bibr" rid="R24">24</xref>); the addition of N in particular was predicted to afford a greater opportunity for T cell responses (<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref>). T cells may provide immune protection at least as important as the generation of antibodies. In a study of SARS-CoV-2 convalescent patients, virus-specific T cells were seen in most patients, including asymptomatic individuals, even those with undetectable antibody responses (<xref ref-type="bibr" rid="R27">27</xref>).</p>
<p id="P5">In our preliminary studies of the hAd5 S-Fusion + N-ETSD vaccine in a murine model, we saw that the vaccine not only elicits T helper cell 1 (Th1)-dominant antibody responses to both S and N, it activates T-cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>). We then looked the potential of the hAd5 S-Fusion + N-ETSD vaccine to re-capitulate T-cell activation prompted by natural SARS-CoV-2 infection (<xref ref-type="bibr" rid="R9">9</xref>). To do this, we transduced monocyte-derived dendritic cells (MoDCs) from SARS-CoV-2 convalescent individuals with the dual-antigen vaccine, incubated the S-Fusion and N-ETSD-expressing MoDCs with T cells from those same individuals, and saw that the vaccine antigens induce interferon-γ (IFN-γ) secretion by both CD4+ and CD8+ T cells (9). This demonstrates that T cells from SARS-CoV-2 convalescent individuals ‘recall’ the S-Fusion and N-ETSD antigens presented by transduced MoDCs as if they were re-exposed to the virus itself. This T-cell recall of vaccine antigens suggests that, conversely, hAd5 S-Fusion + N-ETSD vaccination will generate T cells that will recognize SARS-CoV-2 antigens upon viral infection and protect the vaccinated individual from disease.</p>
<p id="P6">The generation of T-cell responses may be a critical feature for a vaccine to be efficacious against the many variants whose emergence, at least in part, may be an escape response to antibodies generated by either first wave virus (<xref ref-type="bibr" rid="R28">28</xref>) or, as suggested in Wang <italic>et al.</italic> (in preprint) (<xref ref-type="bibr" rid="R29">29</xref>) by antibody-based vaccines. As further reported in Wang <italic>et al.</italic>, neutralization by 14 of 17 of the most potent mRNA vaccine-elicited monoclonal antibodies (mAbs) was either decreased or abolished variants E484K, N501Y or the K417N:E484K:N501Y combination (<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R30">30</xref>). They also found these variants were selected for when recombinant vesicular stomatitis virus (rVSV)/SARS-CoV-2 S was cultured in the presence of these mAbs, which is highly suggestive that the presence of these antibodies act as an evolutionary force driving the appearance of new variants. T cells are not vulnerable to such forces and, if effectively established by vaccination, may provide protection (<xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R33">33</xref>) against existing viral strains and escape mutants.</p>
<p id="P7">We hypothesized that vaccination with the hAd5 S-Fusion + N-ETSD vaccine, which generates both neutralizing antibodies and memory T cells, would be protective in the rhesus macaque and that room temperature oral formulations would be effective as boosts.</p>
<p id="P8">In the next step in development of the hAd5 S-Fusion + N-ETSD vaccine, we formulated GMP (Good Manufacturing Practice)-grade liquid and oral forms of the vaccine for testing in non-human primates (NHP). A key objective of the NHP study design was to assess the efficacy of a subcutaneous (SC) prime followed by a thermally-stable (<xref ref-type="bibr" rid="R34">34</xref>) oral boost.</p>
<p id="P9">An oral boost provides several advantages in SARS-CoV-2 vaccination, including a greater potential for generating mucosal immunity particularly in the gastrointestinal tract (<xref ref-type="bibr" rid="R35">35</xref>) one of the major sites of infection (<xref ref-type="bibr" rid="R36">36</xref>). SARS-CoV-2 is a mucosal virus and is only rarely detected in blood (<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R38">38</xref>), therefore vaccines that specifically target mucosal immunity are of interest (<xref ref-type="bibr" rid="R39">39</xref>). Compelling additional advantages of a thermally-stable oral boost are that it would likely transform the global distribution of vaccines, especially in developing nations and potentially enable patients to self-administer the boost(s) at home. Because the hAd5 S-Fusion + N-ETSD construct induces both humoral and CMI responses to both antigens, it also has the potential to serve as a ‘universal’ heterologous booster vaccine to the multitude of SARS-CoV-2 vaccines under development.</p>
<p id="P10">Here, we report our findings from our study designed to determine the efficacy of the hAd5 S-Fusion + N-ETSD vaccine in rhesus macaques when delivered as either an SC prime with SC and oral boosts (SC-SC-Oral; n =5) or as an SC prime and two oral boosts (SC-Oral-Oral; n = 5) both using a regimen of prime on Day 0 and boosts on Days 14 and 28 to maximize T cell responses. Design details are presented in <italic>Materials and Methods</italic> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. S4</xref>. The goals of the study were to assess the immunogenicity of a dual-antigen hAd5 vaccine in both SC and oral formulations, and the potential of oral dose to serve as a boost following a single SC prime. Most importantly, we sought to assess cell-mediated T-cell response and protection of nasal passages and lung from SARS-CoV-2 infection after challenge as well as the rate of viral clearance.</p>
<sec id="S2">
<title>Clinical signs, hematology and clinical chemistry</title>
<p id="P11">No clinical signs were noted during the twice daily observations for clinical signs of toxicity due to vaccination and no animals died during the two weeks after one subcutaneous immunization of 1x 10<sup>11</sup> vaccine particles (VP) or a week after an oral booster of 1x10<sup>10</sup> IU of hAd5-S-Fusion+N-ETSD. In addition, no gross pathological effects or adverse events were observed and there were no notable changes in body weight (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 5</xref>). Lastly, hematology and clinical chemistry revealed no abnormalities as a result of vaccination (<xref ref-type="supplementary-material" rid="SD1">Supplementary Tables 1 and 2</xref>).</p>
</sec>
<sec id="S3">
<title>An SC prime with oral boosts elicits generation of neutralizing, anti-spike antibodies</title>
<p id="P12">As shown in <xref ref-type="fig" rid="F1">Figure 1</xref>, all SC-Oral-Oral vaccinated NHP produced anti-S IgG that increased after both the Day 14 and Day 28 oral boosts (<xref ref-type="fig" rid="F1">Fig. 1A and B</xref>). Sera from 4 of 5 SC-Oral-Oral NHP, taken at baseline and every week starting at Day 14 and up to Day 42, demonstrated inhibition in the neutralization assay (<xref ref-type="fig" rid="F1">Fig. 1C</xref>) that assesses the inhibition of binding of S RBD to recombinant angiotensin-converting enzyme 2 (ACE2) and is reported to correlate with the ability of sera to neutralize the SARS-CoV-2 virus (<xref ref-type="bibr" rid="R40">40</xref>).</p>
<p id="P13">Anti-S IgG production was similar for SC-SC-Oral (where the first boost was SC) hAd5 S-Fusion + N-ETSD vaccinated NHP (<xref ref-type="fig" rid="F1">Fig. 1D and E</xref>) and sera from all five NHP in this group demonstrated inhibition in the surrogate assay for viral neutralization (<xref ref-type="fig" rid="F1">Fig. 1F</xref>).</p>
</sec>
<sec id="S4">
<title>SC prime, oral boost vaccination reduces viral load in nasal passages and lung after SARS-CoV-2 challenge</title>
<p id="P14">RT-qPCR analysis of genomic RNA (gRNA) was performed on nasal swab and bronchoalveolar lavage (BAL) samples to determine the amount of virus present. SC-Oral-Oral vaccination of NHP reduced SARS-CoV-2 gRNA in the nasal swab samples as compared to placebo control NHP from Day 57, the first day after challenge (<xref ref-type="fig" rid="F2">Fig. 2A and B</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>). Viral gRNA in this group continued to diminish to levels that were very low or below the level of detection (LOD) in all vaccinated animals by Day 63, 7 days after challenge. Placebo controls had moderate to high levels (range 2E+09 – 8.4E+03 gene copies/mL) of SARS-CoV-2 present in nasal swab samples for the duration of the study.</p>
<p id="P15">In the lungs (bronchoalveolar lavage, BAL) of SC-Oral-Oral NHP, gRNA also decreased rapidly, with the geometric mean showing a ∼2 log decrease in vaccinated NHP compared to placebo NHP at Day 57, just one day after challenge (<xref ref-type="fig" rid="F2">Fig. 2C and D</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 4</xref>).</p>
<p id="P16">In the group receiving an SC and oral boost (SC-SC-Oral), SARS-CoV-2 gRNA in nasal swab samples was also reduced similarly to that seen in SC-Oral-Oral vaccinated primates, with viral gRNA decreasing to levels that were very low or below the LOD in all vaccinated animals by Day 63 (<xref ref-type="fig" rid="F2">Fig. 2E and F</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>). In the lungs of SC-SC-Oral NHP, gRNA also showed a ∼2 log decrease on Day 57 (<xref ref-type="fig" rid="F2">Fig. 2G and H</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 4</xref>
<bold>).</bold>
</p>
</sec>
<sec id="S5">
<title>SC prime, oral boost vaccination immediately inhibited viral replication in nasal passages and lung after SARS-CoV-2 challenge</title>
<p id="P17">The presence of replicating virus in nasal swab samples was determined by RT qPCR of subgenomic RNA (sgRNA). By Day 60, 4 days post-challenge, sgRNA was below the LOD for two SC-Oral-Oral primates and, starting on Day 61, below the LOD for all primates that received only oral boosts (<xref ref-type="fig" rid="F3">Figure 3A and B</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 5</xref>).</p>
<p id="P18">In the lungs of SC-Oral-Oral NHP, sgRNA also decreased as compared to placebo starting at Day 57, and was below the LOD in all by Day 63 (<xref ref-type="fig" rid="F3">Fig. 3C and D</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 6</xref>).</p>
<p id="P19">Evidence of replicating viruses in nasal passages also decreased rapidly in SC-SC-Oral NHP and was below the LOD by Day 59 in two primates and in all primates by Day 63 (<xref ref-type="fig" rid="F3">Fig. 3E and F</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 5</xref>); and in the lungs of this group, sgRNA decreased by ∼2 logs compared to placebo control on Day 57, one day after challenge, with sgRNA being below the LOD at Day 63 in 4 of 5 primates, and just above the LOD in the 5<sup>th</sup> (<xref ref-type="fig" rid="F3">Fig. 3 G and H</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 6</xref>).</p>
<p id="P20">Not only was there a rapid decrease of both viral load and replicating viruses in nasal passages and lung, it is notable that there was no growth of viruses following challenge. This implies the presence of pre-existing humoral and cellular immunity resulting in rapid clearance of the virus upon infection.</p>
</sec>
<sec id="S6">
<title>Immediate protection of NHP from SARS-Cov-2 challenge may be due to the presence of T cells responsive to both S and N, and rapid viral clearance to activation of memory B cells</title>
<p id="P21">Peripheral blood mononuclear cell (PBMC)-derived T-cell responses to the antigens delivered by the hAd5 S-Fusion + N+ETSD vaccine, spike and nucleocapsid, were determined by ELISpot on Day 0 before prime vaccination, on Day 14 (before boost) and on Day 35, one week after the second Day 28 boost. T cells from SC-Oral-Oral vaccinated primates secreted interferon-gamma (IFN-γ) in response to both S and N peptides on Days 14 and 35 (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). Interleukin-4 (IL-4) secretion was very low (<xref ref-type="fig" rid="F4">Fig. 4B</xref>), indicating the T-cell responses were T helper cell 1 (Th1) dominant, as reflected by the IFN-g/IL-4 ratio (<xref ref-type="fig" rid="F4">Fig. 4C</xref>).</p>
<p id="P22">For sera collected in the post-challenge period, a microneutralization assay (see Methods) was used to assess SARS-CoV-2 neutralization capability as reflected by the ‘MN50’, that is, the serum dilution that correlates to a 50% reduction in viral infectivity as compared to a no-serum control. A rapid increase in neutralization capability of sera for NHP receiving only oral boosts was seen over the two weeks following challenge (<xref ref-type="fig" rid="F4">Fig. 4D</xref>) that mirrored decreases in nasal gRNA and sgRNA (<xref ref-type="fig" rid="F4">Fig. 4E and F</xref>, respectively) and lung gRNA and sgRNA (<xref ref-type="fig" rid="F4">Fig. 4G and H</xref>, respectively). Notably, sera from placebo group primates did not show an increase in neutralizing capability after challenge (<xref ref-type="fig" rid="F4">Fig. 4D and L</xref>), suggesting the existence of memory B cells in the vaccinated group and the absence of such cells in the unvaccinated placebo group. Further studies are needed to confirm this hypothesis.</p>
<p id="P23">For SC-SC-Oral vaccinated NHP, findings were very similar for reactive T cells during the pre-challenge vaccination period (<xref ref-type="fig" rid="F4">Fig. 4I-K</xref>) and for neutralization capability in the post-challenge period (<xref ref-type="fig" rid="F4">Fig. 4L</xref>), including the mirroring of decreasing gRNA and sgRNA in nasal passages and lung (<xref ref-type="fig" rid="F4">Fig. 4M-P</xref>).</p>
<p id="P24">We hypothesize that the presence of cytotoxic T cells due to vaccination (<xref ref-type="fig" rid="F4">Fig. 4A-C and I-K</xref>) led to the almost immediate decrease in viral replication within the first 24 hours post-challenge (<xref ref-type="fig" rid="F4">Fig. 4F, H, N, and P</xref>), and the continued decreases over the following two weeks that mirrored increases in neutralization capability of sera from vaccinated, but not placebo, NHP reflect the contribution of anti-S-producing memory B cells (<xref ref-type="fig" rid="F4">Fig. 4D and L</xref>).</p>
<p id="P25">This study demonstrates that in the rhesus macaque NHP model, subcutaneous prime and oral boost dual-antigen hAd5 S-Fusion + N-ETSD vaccination protects both nasal and lung airways against SARS-CoV-2 challenge. The inhibition of viral replication in nasal passages as evidenced by decreased sgRNA on the first day after viral challenge was notable, as was continuous clearance of virus to levels below detection within 7 days of challenge in all (10/10) animals (<xref ref-type="fig" rid="F2">Figs. 2</xref> and <xref ref-type="fig" rid="F3">3</xref>); and, while the rhesus macaque is not a model for the assessment of transmission, these rapid reductions in nasal viral replication are encouraging and support the investigation of the ability of this vaccine to prevent transmission in future studies.</p>
<p id="P26">The ability of hAd5 S-Fusion + N-ETSD vaccination to elicit virus-neutralizing anti-S antibodies (<xref ref-type="fig" rid="F1">Fig. 1</xref>) and T cells responsive to both S and N (<xref ref-type="fig" rid="F3">Fig. 3</xref>) - particularly when viewed with the rapid increase in the neutralization capability of sera post-challenge that is likely indicative of the presence of memory B cells - suggests the vaccine establishes broad immunity against severe SARS-CoV-2 infection.</p>
<p id="P27">The potential of the hAd5 S-Fusion + N-ETSD SC prime, oral boost vaccine to generate cytotoxic T cells is, in our opinion, a key feature, given the critical role of T cells play in protection from infection in COVID-19 convalescent patients where SARS-CoV-2 specific T cells were identified even in the absence of antibody responses (<xref ref-type="bibr" rid="R27">27</xref>).</p>
<p id="P28">The apparent nearly immediate reduction of viral replication by the hAd5 S-Fusion + N-ETSD vaccination is in contrast to the reported findings for other adenovirus-vectored S-only vaccine NHP studies (<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref>), wherein there was evidence of continued viral replication in some animals for at least a day after challenge. Even when challenged with the relatively high titer of 1 x10<sup>6</sup> TCID<sub>50</sub>/mL as compared to titers used in some other NHP vaccine studies (<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R41">41</xref>), vaccinated animals in our study appeared to be protected from the earliest time point assessed. This rapid protection and clearance was particularly evident in the lung, where both viral load and viral replication were ∼1-2 logs lower than placebo in both vaccinated groups just one day after challenge.</p>
<p id="P29">The protection conferred by hAd5 S-Fusion + N-ETSD vaccination of NHPs by SC and oral boost administration particularly reveal the potential for this vaccine to be developed for worldwide distribution, especially in light of the escape variants resistant to antibodies and convalescent plasma, now rapidly spreading throughout the world (<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>). The oral hAd5 S-Fusion + N-ETSD formulation would not require ultra-cold refrigeration like many COVID vaccines currently in development. Dependence on the cold-chain for distribution to geographically remote or underdeveloped areas causes shipping and storage challenges and will likely reduce the accessibility of the RNA-based COVID-19 vaccines.</p>
<p id="P30">Our thermally-stable oral hAd5 S-Fusion + N-ETSD vaccine, due its expression of S and N, also has the potential to act as a ‘universal’ boost to other previously administered vaccines that deliver only S antigens. This use would also be facilitated by cold-chain independence and warrants further exploration.</p>
<p id="P31">The hAd5 S-Fusion + N-ETSD vaccine delivered as an SC prime and boost is in Phase 1 clinical trials and the thermally-stable oral vaccine has entered Phase 1 trials as both a prime and boost, and as a boost to an SC prime.</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Materials</label>
<media xlink:href="EMS108044-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="N66520" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S7">
<title>Acknowledgements</title>
<p>We would like to thank the following members of the Battelle group for their contributions in the execution of this study; Chris Cirimotich, Katie Albanese, Phyllis Herr-Calomeni, Bradley Brown, Sara Pfeifer, Carrie Fetzek, Ashley Hay, Andy Puttmann, Amy Allen, and Kevin Coty. We thank Phil Yang of ImmunityBio for his ongoing coordination of project reports for this study. We would also like to thank the DHHS, NIH/NIAID and ASPR/BARDA for funding the study.</p>
</ack>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study</article-title>
<source>The Lancet</source>
<year>2020</year>
<volume>395</volume>
<fpage>689</fpage>
<lpage>697</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>489</fpage>
<lpage>493</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisblum</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title>
<source>Elife</source>
<year>2020</year>
<volume>9</volume>
<fpage>e61312</fpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<etal/>
</person-group>
<article-title>The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>1284</fpage>
<lpage>1294</lpage>
<elocation-id>e1289</elocation-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cele</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma</article-title>
<source>medRxiv</source>
<year>2021</year>
<elocation-id>2021.2001.2026.21250224</elocation-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa</article-title>
<source>medRxiv</source>
<year>2020</year>
<elocation-id>2020.2012.2021.20248640</elocation-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kou</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis</article-title>
<source>Immunology letters</source>
<year>2017</year>
<volume>190</volume>
<fpage>51</fpage>
<lpage>57</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J-Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Improved expression of secretory and trimeric proteins in mammalian cells via the introduction of a new trimer motif and a mutant of the tPA signal sequence</article-title>
<source>Applied Microbiology and Biotechnology</source>
<year>2011</year>
<volume>91</volume>
<fpage>731</fpage>
<lpage>740</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sieling</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2</article-title>
<source>medRxiv</source>
<year>2020</year>
<elocation-id>2020.2011.2004.20225417</elocation-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niazi</surname>
<given-names>KR</given-names>
</name>
<etal/>
</person-group>
<article-title>Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences</article-title>
<source>Immunology</source>
<year>2007</year>
<volume>122</volume>
<fpage>522</fpage>
<lpage>531</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>KY</given-names>
</name>
<etal/>
</person-group>
<article-title>Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen</article-title>
<source>Cancer research</source>
<year>1996</year>
<volume>56</volume>
<fpage>21</fpage>
<lpage>26</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>TC</given-names>
</name>
<etal/>
</person-group>
<article-title>Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>1995</year>
<volume>92</volume>
<fpage>11671</fpage>
<lpage>11675</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mercado</surname>
<given-names>NB</given-names>
</name>
<etal/>
</person-group>
<article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<fpage>583</fpage>
<lpage>588</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Doremalen</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>
<article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<fpage>578</fpage>
<lpage>582</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amalfitano</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted</article-title>
<source>Journal of virology</source>
<year>1998</year>
<volume>72</volume>
<fpage>926</fpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gatti-Mays</surname>
<given-names>ME</given-names>
</name>
<etal/>
</person-group>
<article-title>A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer</article-title>
<source>Oncologist</source>
<year>2019</year>
<volume>25</volume>
<fpage>479</fpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balint</surname>
<given-names>JP</given-names>
</name>
<etal/>
</person-group>
<article-title>Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer</article-title>
<source>Cancer immunology, immunotherapy : CII</source>
<year>2015</year>
<volume>64</volume>
<fpage>977</fpage>
<lpage>987</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabitzsch</surname>
<given-names>ES</given-names>
</name>
<etal/>
</person-group>
<article-title>Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity</article-title>
<source>Vaccine</source>
<year>2009</year>
<volume>27</volume>
<fpage>6394</fpage>
<lpage>6398</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morse</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients</article-title>
<source>Cancer Immunology, Immunotherapy</source>
<year>2013</year>
<volume>62</volume>
<fpage>1293</fpage>
<lpage>1301</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>FR</given-names>
</name>
<etal/>
</person-group>
<article-title>Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine</article-title>
<source>Vaccine</source>
<year>2011</year>
<volume>29</volume>
<fpage>7020</fpage>
<lpage>7026</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabitzsch</surname>
<given-names>ES</given-names>
</name>
<etal/>
</person-group>
<article-title>A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses</article-title>
<source>Immunology letters</source>
<year>2009</year>
<volume>122</volume>
<fpage>44</fpage>
<lpage>51</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabitzsch</surname>
<given-names>ES</given-names>
</name>
<etal/>
</person-group>
<article-title>Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine</article-title>
<source>Vaccine</source>
<year>2011</year>
<volume>29</volume>
<fpage>8101</fpage>
<lpage>8107</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maruyama</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs</article-title>
<source>Vaccine</source>
<year>2019</year>
<volume>37</volume>
<fpage>6824</fpage>
<lpage>6831</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>T-cell-inducing vaccines - what's the future</article-title>
<source>Immunology</source>
<year>2012</year>
<volume>135</volume>
<fpage>19</fpage>
<lpage>26</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Bert</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>457</fpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>1489</fpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekine</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>158</fpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition</article-title>
<source>Cell Host Microbe</source>
<year>2020</year>
<comment>S1931-382 3128(1920)30624-30627</comment>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.2001.2015.426911</elocation-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zahradník</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.2001.2006.425392</elocation-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hellerstein</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?</article-title>
<source>Vaccine: X</source>
<year>2020</year>
<volume>6</volume>
<elocation-id>100076</elocation-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Channappanavar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fett</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meyerholz</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection</article-title>
<source>Journal of virology</source>
<year>2014</year>
<volume>88</volume>
<fpage>11034</fpage>
<lpage>11044</lpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMahan</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title>
<source>Nature</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1038/s41586-020-03041-6</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Drew</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Use of adenovirus as a model system to illustrate a simple method using standard equipment and inexpensive excipients to remove live virus dependence on the cold-chain</article-title>
<source>Vaccine</source>
<year>2014</year>
<volume>32</volume>
<fpage>2931</fpage>
<lpage>2938</lpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmgren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Czerkinsky</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Mucosal immunity and vaccines</article-title>
<source>Nature Medicine</source>
<year>2005</year>
<volume>11</volume>
<fpage>S45</fpage>
<lpage>S53</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Evidence for Gastrointestinal Infection of SARS-CoV-2</article-title>
<source>Gastroenterology</source>
<year>2020</year>
<volume>158</volume>
<fpage>1831</fpage>
<lpage>1833</lpage>
<elocation-id>e1833</elocation-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Locatello</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Mazzoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Novelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Annunziato</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection</article-title>
<source>Mucosal Immunol</source>
<year>2020</year>
<fpage>1</fpage>
<lpage>12</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>HQ</given-names>
</name>
<etal/>
</person-group>
<article-title>Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients</article-title>
<source>Eur Respir J</source>
<year>2020</year>
<volume>56</volume>
<elocation-id>2001526</elocation-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreno-Fierros</surname>
<given-names>L</given-names>
</name>
<name>
<surname>García-Silva</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rosales-Mendoza</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?</article-title>
<source>Expert Opinion on Biological Therapy</source>
<year>2020</year>
<volume>20</volume>
<fpage>831</fpage>
<lpage>836</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>CW</given-names>
</name>
<etal/>
</person-group>
<article-title>A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction</article-title>
<source>Nat Biotechnol</source>
<year>2020</year>
<volume>38</volume>
<fpage>1073</fpage>
<lpage>1078</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques</article-title>
<source>Nature communications</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>4207</elocation-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>281</fpage>
<lpage>292</lpage>
<elocation-id>e286</elocation-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Biochemical characterization of SARS-CoV-2 nucleocapsid protein</article-title>
<source>Biochemical and biophysical research communications</source>
<year>2020</year>
<comment>S0006-0291X(0020)30876-30877</comment>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
<fpage>360</fpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Firmal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ganguly</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past</article-title>
<source>Front Immunol</source>
<year>2020</year>
<volume>11</volume>
<fpage>1949</fpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sattler</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition</article-title>
<source>The Journal of Clinical Investigation</source>
<year>2020</year>
<volume>130</volume>
<fpage>6477</fpage>
<lpage>6489</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaack</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Promoter strength in adenovirus transducing vectors: down-regulation of the adenovirus E1A promoter in 293 cells facilitates vector construction</article-title>
<source>Virology</source>
<year>2001</year>
<volume>291</volume>
<fpage>101</fpage>
<lpage>109</lpage>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilkinson</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Akrigg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector</article-title>
<source>Nucleic Acids Res</source>
<year>1992</year>
<volume>20</volume>
<fpage>2233</fpage>
<lpage>2239</lpage>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>CW</given-names>
</name>
<etal/>
</person-group>
<article-title>A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction</article-title>
<source>Nat Biotechnol</source>
<year>2020</year>
<volume>38</volume>
<fpage>1973</fpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wölfel</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Virological assessment of hospitalized patients with COVID-2019</article-title>
<source>Nature</source>
<year>2020</year>
<volume>581</volume>
<fpage>465</fpage>
<lpage>469</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Thurston</surname>
<given-names>RV</given-names>
</name>
</person-group>
<article-title>Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays</article-title>
<source>Environmental Science &amp; Technology</source>
<year>1977</year>
<volume>11</volume>
<fpage>714</fpage>
<lpage>719</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<boxed-text id="BX1" position="float" orientation="portrait">
<sec id="S8">
<title>One Sentence Summary</title>
<p>hAd5 spike + nucleocapsid SC prime/oral boost vaccine elicits humoral and T-cell responses and protects rhesus macaques from SARS-CoV-2 challenge.</p>
</sec>
</boxed-text>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<title>Humoral responses and neutralizing capability of sera from hAd5 S-Fusion + N-ETSD vaccinated NHP.</title>
<p>Anti-spike IgG levels (ELISA; OD 450nm) are shown for (A) individual SC-Oral-Oral NHP along with the (B) geometric mean and (C) inhibition in the surrogate assay. These data are also shown for SC-SC-Oral NHP: (D) individual anti-S IgG, (E) geometric mean, and (F) inhibition in the surrogate assay. Inhibition above 20% (dashed line) with a sera dilution of 1:30 is correlated with neutralization of SARS-CoV-2 infection. NHP received vaccination on Days 0, 14 and 28 (black arrows).</p>
</caption>
<graphic xlink:href="EMS108044-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<title>Viral load (gRNA) in nasal passages and lung of SC-Oral-Oral and SC-SC-Oral vaccinated NHP post-challenge.</title>
<p>(A) Individual viral gRNA (RT qPCR) and (B) the geometric mean for nasal swab samples; and (C) gRNA and (D) the geometric mean for bronchoalveolar lavage (BAL) samples from SC-Oral-Oral NHP. (E) Individual gRNA and (F) the geometric mean for nasal swab samples; and (G) gRNA and (H) the geometric means for BAL samples from SC-SC-Oral NHP. SARS-CoV-2 challenge was on Day 56 (black arrows). The level of detection (LOD; dashed line) was 54 gene copies/mL (GC/mL) for gRNA and 119 GC/mL for sgRNA. For values below the LOD, half the LOD value (or 27 GC/mL for gRNA and 59 GC/mL for sgRNA) was used for graphing of individual values and calculation of the geometric mean.</p>
</caption>
<graphic xlink:href="EMS108044-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<title>Viral replication (sgRNA) in nasal passages and lung in SC-Oral-Oral and SC-SC-Oral vaccinated NHP post-challenge.</title>
<p>(A) Individual viral sgRNA (RT qPCR) and (B) the geometric mean for nasal swab samples; and (C) sgRNA and (D) the geometric mean for bronchoalveolar lavage (BAL) samples from SC-Oral-Oral NHP. (E) Individual sgRNA and (F) the geometric mean for nasal swab samples; and (G) sgRNA and (H) the geometric means for BAL samples from SC-SC-Oral NHP. SARS-CoV-2 challenge was on Day 56 (black arrows). The level of detection (LOD; dashed line) was 54 gene copies/mL (GC/mL) for gRNA and 119 GC/mL for sgRNA. For values below the LOD, half the LOD value (or 27 GC/mL for gRNA and 59 GC/mL for sgRNA) was used for graphing of individual values and calculation of the geometric mean.</p>
</caption>
<graphic xlink:href="EMS108044-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig. 4</label>
<caption>
<title>T-cell responses to vaccination and neutralization capability of sera post-SARS-CoV-2 challenge.</title>
<p>(A) Interferon-γ (IFN-γ) and (B) interleukin-4 (IL-4) secretion by PBMC-derived T cells from SC-Oral-Oral vaccinated NHP in response to spike (S) and nucleocapsid (N) peptides as determined by ELISpot as well as (C) the ratio IFN-γ/IL-4 ratio are shown. Ratios of ‘infinity’ due to undetectable IL-4 are represented as open circles. Cells pulsed with PMA-ionomycin were used as positive controls as described in <italic>Methods</italic> (not presented). Data graphed with mean and SEM. (D) MN50 (dilution factor which SARS-CoV-2 infection of Vero E6 cells is inhibited by 50%) throughout the course of the study is shown; an unpaired, two-tailed Student’s t-test was used to compare MN50s for vaccinated and placebo NHP on Day 70. Nasal gRNA (E) and sgRNA (F) on Days 57, 63 and 70, as well as lung gRNA (G) and sgRNA on Days 57 and 63 are presented. The same data are shown for SC-SC-Oral NHP, including T-cell responses (I-J), MN50 (L), nasal gRNA (M) and sgRNA (N), as well as lung gRNA (O) and sgRNA (P). The level of detection for gRNA was 54 gene copies/mL (GC/mL) and for sgRNA was 119 GC/mL. Half the LOD was used for graphing of data below the LOD.</p>
</caption>
<graphic xlink:href="EMS108044-f004"/>
</fig>
</floats-group>
</article>
